An artificial intelligence company and a biotech investment firm are joining forces to use AI in the search for new medicines.
Edison Scientific, described as an "AI scientist" company, is partnering with the investment firm Population Health Partners to apply AI agents to drug discovery and development, according to STAT News. The two plan to use that technology to help create new biotech companies.
Population Health Partners is notable because, as STAT News reports, it is the team behind Metsera. That track record is part of why the tie-up is drawing attention: it pairs an AI-focused company with investors who have already built a biotech.
The core idea is to put AI "agents" — software that can carry out multi-step tasks with some autonomy — to work on the slow, expensive process of finding and developing new drugs. Rather than simply consulting on existing projects, the partners say they intend to use the approach to launch entirely new biotechs.
Details beyond the partnership itself are limited in the available reporting. The sources confirm who is involved and the broad aim — leveraging AI agents in drug discovery to create new companies — but do not specify funding figures, timelines, or which diseases the new biotechs would target.
Why it matters: Drug discovery is famously costly and failure-prone, and a growing number of companies are betting that AI can speed it up; this deal is a concrete test of whether pairing AI tools with experienced biotech investors can actually produce new medicines.